This review highlights advancements in tuberculosis diagnostics, suggesting new methods and technologies may improve accuracy and speed.
Tuberculosis remains the leading cause of death by a single infectious agent worldwide, with over 10 million cases annually. Despite global efforts, delayed or missed diagnoses continue to fuel transmission and mortality, particularly in resource-limited settings. This review outlines both the current diagnostic standards - microscopy, culture, and nucleic acid amplification tests - and highlights promising innovations aimed at improving diagnosis of tuberculosis disease. Novel approaches include stool polymerase chain reaction (PCR), CRISPR (clustered regularly interspaced short palindromic repeats)-based detection of circulating cell-free DNA (cfDNA), transcriptomic signatures, molecular bacterial load assay (MBLA), lipoarabinomannan (LAM) detection in urine or sputum, and non-invasive sampling techniques using exhaled breath condensate, face masks or oral swabs. Furthermore, advancements in imaging technologies and AI (artificial intelligence)-based tools may enhance diagnostic accuracy. Together, these developments have the potential to accelerate and simplify tuberculosis diagnostics in the future.
No takes yet. Share an insight, caveat, or question.
Mischnik et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: